Caplin Point Laboratories has been recognized in Forbes Asia's 200 Best Under a Billion list for the year 2023, a compilation that underscores companies' sustained and robust performance across critical benchmarks. Carefully selected from a substantial pool of more than 20,000 publicly traded companies across the Asia-Pacific region, the chosen 200 enterprises showcase annual sales under $1 billion. The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
